

PLATTEN, MICHAEL, PROF. DR. MED.

GENERAL INFORMATION



Chairman/Head

Heidelberg University, Mannheim Medical Faculty; Department of Neurology
Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology
German Cancer Research Center (DKFZ)
Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany

B01

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2006	Board Certification in Neurology, University of Tübingen
1991 - 1998	Medical School, University of Bonn (Germany), University of London (England) and Harvard Medical School (Boston, USA)

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2006	Habilitation in Neurology, University of Tübingen, Mentor: Johannes Dichgans
1998	MD, Department of Neuropathology, University of Bonn, Supervisor: A. v. Deimling

PROFESSIONAL EXPERIENCE

Year(s)	Experience
2016 - present	Full Professor (W3) of Neurology, Heidelberg University and Chairman, Department of Neurology, University Hospital Mannheim
2015 - 2016	Full Professor (W3) of Neuroimmunology, German Cancer Research Center Heidelberg
2014 - 2016	Vice chair, Department of Neurology, Heidelberg Medical Center, University of Heidelberg
2013 - present	Head Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center
2010 – 2015	Associate Professor (W3) of Experimental Neuroimmunology, University of Heidelberg
2007 - 2013	Head Helmholtz University Young Investigator Group Experimental Neuroimmunology, German Cancer Research Center
2007 - 2014	Vice chair and senior attending, Department of Neurooncology, University of Heidelberg
2006 - 2007	Attending, Department of Neurology, University of Tübingen
2002 – 2004	Postdoctoral Fellowship, Department of Immunology, Stanford University, USA
1999 - 2006	Residency in Neurology, University of Tübingen

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
	Editorial Boards (selected)
2017 - present	Editorial Board Journal of ImmunoTherapy of Cancer
2016 – present	Editorial Board Neuro-Oncology
	Honors (selected)
2019	German Cancer Award
2012	Sir Hans Krebs Award
2011	Chica und Heinz Schaller Award
2010	Heinrich Pette Award
	Coordinating Functions (selected)
2019 - present	Founding Director, Mannheim Center for Translational Neurosciences, Medical Faculty Mannheim, Heidelberg University
2018 - present	Coordinator, Research Topic Immunology and Cancer, German Cancer Research Center
2017 - present	Chair, Scientific Committee, European Association of Neuro-Oncology

2014 - present	Board member of the Neurooncology Working Group (NOA) of the German Cancer Society
----------------	--

SELECTED PUBLICATIONS

1. Sonner JK*, Keil M*, ..., Wick W, Bode HB, Rosenstiel P*, Platten M*. Dietary tryptophan links encephalitogenicity of autoreactive T cells with gut microbial ecology. **Nat Commun** 2019;10(1):4877. *equal contribution
2. Bunse L*, Pusch S*, Bunse T*, Sahm F, ..., von Deimling A, Wick W, Platten M. Suppression of antitumor T cell immunity by the oncometabolite R-2-hydroxyglutarate. **Nat Med** 2018;24(8):1192-1203. *equal contribution
3. Hilf N*, Kuttruff-Coqui S*, ..., Platten M, ..., Sahin U, Dietrich PY, Wick W. First-in-human trial of actively personalized vaccination in newly diagnosed glioblastoma. **Nature** 2019;566:240-255. * equal contribution
4. Kirschbaum K, Sonner JK, ..., Heiland S, Bendszus M, Platten M, Breckwoldt MO. In vivo nanoparticle imaging of the innate immune cell compartment can serve as a biomarker of disease severity in a mouse model of multiple sclerosis. **Proc Natl Acad Sci USA** 2016;113:13227-13232
5. Bunse L, Schumacher T, Sahm F, Pusch S, Oezen I, Rauschenbach K, Gonzalez M, Solecki G, Osswald M, Capper D, Wiestler B, Winkler F, Herold-Mende C, von Deimling A, Wick W, Platten M. Proximity ligation assay evaluates IDH1R132H presentation in gliomas. **J Clin Invest** 2015;125:593-606
6. Osswald M, Jung E, Sahm F, Solecki G, Blaes J, Weil S, Venkataramani V, Horstmann H, Wiestler B,, Pusch S, Herl V, Steinhäuser C, Kronic D, Jarahian M, Miletic H, Berghoff A, Griesbeck O, Garaschuk O, Preusser M, Weiss S, Liu H, Heiland S, Platten M, Huber PE, Kuner T, von Deimling A, Wick W, Winkler F. Brain tumor cells interconnect to a functional and resistant network. **Nature** 2015;528:93-98
7. Schumacher T, Bunse L, Pusch S, Sahm F, ..., von Deimling A, Wick W, Platten M. A vaccine targeting mutant IDH1 induces antitumor immunity. **Nature** 2014;512:324-327
8. Bessedé A, ..., Lanz TV, Platten M, ..., Grohmann U, Fallarino F, Puccetti P. Aryl hydrocarbon receptor control of a disease tolerance defense pathway. **Nature** 2014;511:184-192
9. Lanz TV, ..., von Deimling A, Winkler F, Meuth SG, Wick W, Platten M. Endothelial protein kinase C β as a therapeutic target stabilizing blood brain barrier disruption in experimental autoimmune encephalomyelitis. **Proc Natl Acad Sci USA** 2013;110:14735-14740
10. Opitz CA*, Litzenburger UM*, Sahm F, ..., von Deimling A, Wick W, Platten M. An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation. **Nature** 2011;478:197-203 *equal contribution

PATENTS

- Weller M, Wick W, Wischhusen J, Platten M. A method of modulating cellular activity and agents useful for the same (US 7531575 B2)
- Steinman L, Platten M, Ho PP, Selley ML. Method of modulating T cell functioning (US20080009519A1)
- Kaper T, Platten M, Steinman L, Frommer W. Trp/his exchange and kynurenine induced Trp transport (US7935494B2)
- Platten M, Opitz C, Wick W, Litzenburger U. Means and methods for treating and/or preventing natural AHR ligand-dependent cancer (EP2753315B1)
- Schmees N, Gutcher I, Irlbacher H, Bader B, Zhao N, Platten M, Roehn U, Zorn L, Roese L, Stoeckigt D. 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides (EP3464248A1)
- Platten M, Schumacher T, Wick W. Peptides for use in treating or diagnosing IDH1R132H positive cancers (EP2800580B1)
- Platten M, Bunse T, Wick W, Ochs K, Ott M, Bunse L. Histone anti-cancer vaccines (US20180155403A1)
- Koncarevic S, Kuhn K, Schulz-Knappe P, Pike IH, Opitz C, Platten M. Isotopic methods for measurement of tryptophan and metabolites thereof (US20180246118A1)
- Platten M, Wick W, Bunse L, Bunse T, Sahm F. Method for the detection of antigen presentation (US20170254803A1)
- Gutcher I, Roehn U, Schmees N, Zorn L, Roese L, Bader B, Kober C, Carretaro R, Stoeckigt D, Irlbacher H, Platten M. 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer (WO2018146010A1)
- Gutcher I, Roehn U, Zorn L, Roese L, Bader B, Kober C, Carretaro R, Stoeckigt D, Platten M. 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides (WO2019101643A1)
- LeFranc J, Schmees N, Roehn U, Zorn L, Guenther J, Gutcher I, Roese L, Bader B, Stoeckigt D, Platten M. 2-phenylpyrimidine-4-carboxamides as AHR inhibitors (WO2019101647A1)

- LeFranc J, Schmees N, Roehn U, Zorn L, Guenther J, Gutcher I, Roese L, Bader B, Stoeckigt D, Platten M. 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists (WO2019101641A1)
- Zorn L, Roehn U, Gutcher I, Roese L, Bader B, Kober C, Carretaro R, Stoeckigt D, Platten M. Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides (WO2019101642A1)